Gene Therapy Supply Runs Out, Company Warns of Treatment Delays
(MedPage Today) -- Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily unavailable, according to maker CSL Behring. In a letter addressed to the hemophilia B community, the company...
Source
MedPage Today
Opens original article in a new tab